John Theurer Cancer Center at Hackensack University Medical Center Research Helps Establish Durable Responses After KTE-X19

ZUMA-2 study long-range follow-up in relapsed/refractory mantle cell lymphoma (R/R MCL)

John Theurer Cancer Center at Hackensack University Medical Center researchers helped identify factors associated with long-term response to KTE-X19 (brexu-cel), evaluated patient and product characteristics by response status at 24 mo post infusion in ZUMA-2. Results were published in Blood. Here are a few notable findings:

• After ~3-years median follow-up, brexu-cel continues to demonstrate durable responses with 49% of patients in ongoing response at 24 months post infusion.
• Ongoing responders had lower ECOG scores and tumor burden, as well as less frequent use of bridging therapy and less intense regimens for previous relapses.
• Study suggests the potential for greater benefit with brexu-cel if given in earlier course of disease.

A modest increase in the median total number of infused CCR7+ cells was observed in ongoing vs. relapsed responders suggesting continuous memory T-Cell differentiation could potentially have a role in achieving durable responses.

Learn more about innovations in cancer treatments at Hackensack University Medical Center.